Results 51 to 60 of about 3,887,212 (164)

The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Somatostatin receptor 2 is expressed in nasopharyngeal carcinoma (NPC). We report genomic and transcriptomic analysis results of 163 NPC cases, demonstrating that somatostatin receptor 2 (SSTR2) gene expression in EBV‐positive and in EBV‐negative NPC correlated with genomic alterations and an inflamed microenvironment.
Dara Bracken‐Clarke, Elisabetta Xue, Harris Krause, Tolulope Adeyelu, Mark G. Evans, Dilara Akbulut, Martha Quezado, Nishant Gandhi, Alex Farrell, Heloisa P. Soares, Emil Lou, Minh Phan, Rusha Patel, Ari M. Vanderwalde, Andrew Elliott, Conor E. Steuer, Nabil F. Saba, Daniel J. Lubin, Nyall R. London Jr, James L. Gulley, Charalampos S. Floudas   +20 more
wiley   +1 more source

Peptide receptor radionuclide therapy.

, 2004
On their plasma membranes, cells express receptor proteins with high affinity for regulatory peptides, such as somatostatin. Changes in the density of these receptors during disease, for example, overexpression in many tumors, provide the basis for new ...
Kvols, LK, Krenning, Eric P, MARION DE JONG, De Jong, Marion, Pauwels, Stanislas, DIK J. KWEKKEBOOM, Kvols, Larry K, Krenning, Eric, Pauwels, S, Kwekkeboom, Dik J, ERIC P. KRENNING, Valkema, R., Jong, Marion, Valkema, Roelf, Kwekkeboom, Dik, ROELF VALKEMA, STANISLAS PAUWELS, LARRY K. KVOLS   +17 more
core   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source

Supplementary Material for: Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation

, 2017
Background: Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the patients eventually developing metastases. Neuroendocrine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been ...
Zaniboni A. (4135816), Rodella C. (4135813), Nisa L. (4135807), Bertagna F. (4135801), Bettinsoli G. (4135819), Biasiotto G. (4135810), Bosio G. (4135822), Peli A. (4135825), Savelli G. (4135828), Migliorati E. (4135804)   +9 more
core   +1 more source

Complete loss of E-cadherin expression in a rare case of metastatic malignant meningioma: a case report

BMC Neurology, 2023
Background Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis. Case presentation We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones ...
Dominik Lisowski, Philipp E. Hartrampf, Natalie Hasenauer, Vera Nickl, Camelia-Maria Monoranu, Jörg Tamihardja   +5 more
doaj   +1 more source

The Crystal Structure Elucidation of a Tetrapeptide Analog of Somatostatin DOTA-Phe-D-Trp-Lys-Thr-OMe

Crystals, 2021
Herewith, we report for the first time the crystal structure of tetrapeptide FwKT (Phe-D-Trp-Lys-Thr), which is considered to represent an epitope for biomedically relevant hormone somatostatin.
Sabina Diusenova, Sergey Arkhipov, Dmitry Avdeev, Pavel Dorovatovskii, Derenik Khachatryan, Vladimir Lazarenko, Michael Medvedev, Alena Nikolaeva, Mikhail Ovchinnikov, Maria Sidorova, Yan Zubavichus   +10 more
doaj   +1 more source

Peptide receptor radionuclide therapy of neuroendocrine tumours

, 2016
In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an
Brabander, Tessa, van Eijck, Casper, de Herder, W.W., Franssen, Gaston, Teunissen, Jaap, Feelders, R.A., Kwekkeboom, Dik   +6 more
core   +1 more source

Translating Asian‐Dominant Pivotal Evidence Into EU Marketing Authorization: An EMA Regulatory Document Analysis, 2021–2025

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT An increasing number of novel molecular entities and biosimilars reach the European Medicines Agency (EMA) supported by pivotal evidence derived predominantly from Asian patient populations. This creates regulatory challenges that the existing ICH E5 framework was not originally designed to address.
Prerona Boruah, Alex Zwiers
wiley   +1 more source

Improvement strategies for peptide receptor scintigraphy and radionuclide therapy

, 2008
Somatostatin receptor-targeting peptides are widely used for the imaging and therapy of neuroendocrine tumors. Peptide-receptor radionuclide therapy (PRRT) in neuroendocrine tumor patients with radiolabeled somatostatin analogs has resulted in ...
Visser, Martijn, Jong, Marion, Verwijnen, SM   +2 more
core   +1 more source

Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

, 2020
Background Therapy-related leukemia is a well-recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic ...
Selin Kucukyurt, Ercaliskan, Abdulkadir, KABASAKAL, Levent, Levent Kabasakal, Ahmet Emre Eskazan, Yeliz Yagiz Ozogul, Kucukyurt, Selin, Abdulkadir Ercaliskan, EŞKAZAN, Ahmet Emre, Yagiz Ozogul, Yeliz   +9 more
core   +1 more source